BeOne Medicines

BeOne's 2026 shareholder letter says the company's in-house development model has integrated AI and automation, and that BeOne is expanding the use of AI to optimize clinical trial design and accelerate recruitment. The same passage says the company has already shortened protocol-development time, sped proof-of-concept decisions and improved clinical-trial site monitoring.

BeOne's 2025 sustainability report says the company set budgetary targets to advance non-animal research tools through its in-house computational drug design and AI drug discovery groups. It says those groups now play an active role in every BeOne research program.

BeOne says it leverages assistive AI and digital tools to analyze safety data more efficiently and to speed the identification of potential risks. The statement sits in the report's description of its in-house global patient-safety and pharmacovigilance work.

BeOne says it recently convened a Patient Advocacy AI Innovation Lab with members of the blood-cancer community to discuss patient and caregiver needs, how to harness the technology, and how to guide patients in using AI tools. The same article says BeOne is using those insights to develop new digital tools to help patients, including people living with chronic lymphocytic leukemia, navigate their care.